Clinical trials: Prostate Cancer
Prostate, Prostate Cancer
Focal Therapy in Localized Prostate Cancer: a Prospective Registry
The principal aim of the registry is to collect data on focal therapy (FT) for the treatment of intermediate-risk prostate cancer across Europe.
- Trial name
- JR (NCT06772116)
- Testing
- Focal Therapy
- Volunteers
- 1,000 people
- Sponsor
- Institut Mutualiste Montsouris
Prostatic Neoplasm, Lower Urinary Tract Symptoms
Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer
The aim of this study is to investigate the safety and efficacy of prostatic artery embolization of patients with recurrent symptoms secondary to locally advanced prostatic cancer including pelvic pain, bleeding or need for…
- Conditions
- Prostatic Neoplasm, Lower Urinary Tract Symptoms, Urological Manifestations, Prostatic Diseases
- Trial name
- NCT03104907
- Testing
- Prostatic Artery Embolization
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as triptorelin and flutamide, may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00104741
- Testing
- flutamide, triptorelin, radiation therapy
- Where
- 31 sites in France
- Volunteers
- 378 people
- Sponsor
- UNICANCER
Localised Prostate Cancer, Locally Advanced Prostate Cancer
MRI Guided Transurethral HIFU for Various Prostate Diseases
This study assesses feasibility and safety, the primary outcomes, of MRI guided transurethral high intensity focused ultrasound (HIFU) ablation for prostate diseases (PD).
- Conditions
- Localised Prostate Cancer, Locally Advanced Prostate Cancer, Locally Recurrent Prostate Cancer, Benign Prostatic Hyperplasia
- Trial name
- HIFU-PRO (NCT03350529)
- Testing
- MRI guided transurethral HIFU ablation of prostatic tissue
- Where
- Finland
- Volunteers
- 87 people
- Sponsor
- Turku University Hospital
Prostate Cancer
The PROSECCA Study, Answering New Questions in Prostate Cancer
Nearly half of all cancer patients receive radiotherapy as part of their treatment and although it is effective at destroying cancerous lesions deep within the body, this comes at the cost of damaging healthy, or normal, tissues.
- Trial name
- PROSECCA (NCT06714630)
- Where
- United Kingdom
- Volunteers
- 15,000 people
- Sponsor
- University of Edinburgh
Prostate Cancer
A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme
In this study, the investigators aim to determine if the Vienna nomogram increases the detection rate of TRUS-guided prostate biopsies by conducting a prospective randomized study comparing the Vienna nomogram with a 10-core…
- Trial name
- NCT01752140
- Testing
- 10-core prostate biopsy protocol, Vienna nomogram prostate biopsy protocol
- Where
- Portugal
- Volunteers
- 463 people
- Sponsor
- Hospital de Santa Maria, Portugal
Prostate Cancer
Asia Study Group of Prostate Cancer (A-CaP Study)
This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine…
- Trial name
- NCT02873013
- Where
- Japan
- Volunteers
- 20,000 people
- Sponsor
- Japan Study Group of Prostate Cancer
Prostate Cancer
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Hormone therapy combined with radiation therapy may be a more effective treatment for prostate cancer.
- Trial name
- NCT00769548
- Testing
- flutamide, goserelin acetate, low-LET photon therapy
- Volunteers
- 1,322 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
An Exercise Trial and Economic Analysis in Men With Prostate Cancer
Prostate Cancer (PC) affects 1 in 7 men. Nearly half of those diagnosed with PC will receive androgen deprivation therapy (ADT) as part of their treatment. ADT is good at managing PC but has many side effects.
- Trial name
- ADT Ex RCT (NCT02046837)
- Testing
- Supervised 1:1 exercise, Supervised group exercise, Home-based exercise
- Where
- 2 sites in Canada
- Volunteers
- 59 people
- Sponsor
- University Health Network, Toronto
Prostate Carcinoma, Recurrent Prostate Carcinoma
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection.
- Trial name
- NCT04857502
- Testing
- 99mTc-based PSMA Imaging and Surgery Agent, Computed Tomography, Single Photon Emission Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective Trial
This is prospective single-arm case-control study designed to compare in parallel PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy ("experimental test") with mpMRI/TRUS fusion prostate biopsy ("standard test") in men…
- Trial name
- PROSPET-BX (NCT05297162)
- Testing
- PSMA PET/TRUS (trans-rectal or trans-perineal) fusion biopsy
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- Istituto Clinico Humanitas
Prostate Cancer
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005048
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- NYU Langone Health
Metastatic Castration Resistant Prostate Cancer
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined…
- Trial name
- PREMISE (NCT02495974)
- Testing
- enzalutamide
- Where
- 182 sites in Austria, Belgium and 14 more
- Volunteers
- 1,763 people
- Sponsor
- Astellas Pharma Europe Ltd.
Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate…
- Trial name
- NCT07428642
- Testing
- Androgen Deprivation Therapy, Apalutamide, Enzalutamide
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate…
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02012296
- Testing
- enzalutamide, mifepristone, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- University of Chicago
Prostate Cancer (Diagnosis), Quality of Life
Turkish Version of the UCLA Prostate Cancer Index
This study will evaluate the cross-cultural adaptation, validity, and reliability of the Turkish version of the UCLA Prostate Cancer Index in men diagnosed with prostate cancer.
- Conditions
- Prostate Cancer (Diagnosis), Quality of Life, Reliability, Validity
- Trial name
- NCT07448545
- Testing
- Questionnaires
- Where
- Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Lokman Hekim University
Metastatic Cancer, Prostate Cancer
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for prostate cancer.
- Trial name
- NCT00002503
- Testing
- strontium chloride Sr 89
- Where
- 21 sites in Belgium, Denmark and 7 more
- Volunteers
- 204 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
PROSTATE CANCER, Prostate Biopsy
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
The goal of this cohort study is to investigate multiparametric ultrasound versus multiparametric MRI for clinically significant prostate cancer detection in patients scheduled for initial biopsy.
- Trial name
- TRUSVSMPMRI (NCT06183905)
- Testing
- Prostate imaging, Prostate biopsy
- Where
- China
- Volunteers
- 635 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK